ArticleNeuro-oncology2020
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Radhika Mathur et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
60 papers cite it
this paperpooled itcites it